|Bid||0.0000 x N/A|
|Ask||0.0000 x N/A|
|Day's range||0.0000 - 0.0000|
|Beta (5Y monthly)||0.75|
|PE ratio (TTM)||N/A|
|Earnings date||27 Mar 2023 - 31 Mar 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Adverum (ADVM) initiates dosing in the phase II LUNA study, currently investigating its lead product candidate ixoberogene soroparvovec for wet age-related macular degeneration.
Generally, when a single insider buys stock, it is usually not a big deal. However, when several insiders are buying...